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Objective/Purpose: The objective was to identify inﬂammatory biomarkers that predict risk of 90-daymortality in
patients with acute dyspnea.
Method:We analyzed 25 inﬂammatory biomarkers, in plasma, in 407 adult patients admitted to the emergency
department (ED)with acute dyspnea and related them to risk of 90-daymortality using Cox proportional hazard
models adjusted for age, sex, oxygen saturation, respiratory rate, C-reactive protein, andMedical Emergency Tri-
age and Treatment System–Adult score.
Results: Fifty patients (12%) died within 90 day from admission. Two strong and independent biomarker signals
were detected: The hazard ratio (95% conﬁdence interval) for 90-day mortality per 1-SD increment of
interleukin-8 (IL-8) was 2.20 (1.67-2.90) (P= 2.5 × 10−8) and for growth differentiation factor–15 (GDF-15)
was 3.45 (2.18-5.45) (P = 1.3 × 10−7) A Biomarker Mortality Risk Score (BMRS) summing standardized and
weighted values of IL-8 and GDF-15 revealed that of patients belonging to quartile 1 (Q1) of the BMRS, only 1 pa-
tient died, whereas 32 patients died among those belonging to quartile 4. Each 1-SD increment of the BMRS was
associated with a hazard ratio of 3.79 (2.50-5.73) (P= 2 × 10−10) for 90-day mortality, and the point estimate
was 13 times higher in Q4 as compared with Q1 of the BMRS (Ptrend over quartiles = 2 × 10−6).
Conclusion: Interleukin-8 and GDF-15 are strongly and independently related to risk of 90-daymortality in unse-
lected patients admitted to the ED because of acute dyspnea, suggesting that theymay guide ﬁrst-line physicians
at the ED in risk assessment which in turn could lead to more accurate level of care and treatment intensity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Background
Dyspnea is one of the most common symptoms at the emergency de-
partment (ED), accounting for approximately 3-4 million visits in the ED
every year in the United States [1]. The underlying differential diagnoses
are diverse and range from conditions with high risk of mortality to virtu-
ally no risk of mortality at all. Chronic diseases such as congestive hearturopean Research Council (StG-
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ospital, the Albert Påhlsson Re-
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. This is an open access article underfailure (CHF) and chronic obstructive pulmonary disease (COPD) are com-
mon inpatientswith acute dyspneaaswell as infections, pulmonary embo-
lism, and anxiety disorders. Physical examination, history, laboratorywork,
and imaging techniques are used in assessing the cause [2]. However, the
identiﬁcation of the correct diagnosis is just one step toward correctly
treating the patient, and sometimes, the main underlying cause of acute
dyspnea is not unmasked until during hospitalization or after the patient
has left the ED. An equally important task for the physician at the ED is to
make decisions of intensity of treatment and level of care, or follow-up in
the case of hospital discharge. One of the key factors to take into account
as a basis for these decisions is the patient’s risk of long-termmortality.
Not only in infections but also in chronic diseases, for example, CHF
and COPD, has inﬂammation been suggested be a part of the patholog-
ical processes [3,4]. By deﬁnition, inﬂammation is a protective tissue re-
sponse to injury or destruction of tissues, which aims at eliminating the
injurious agent and the injured tissues. Clinically and epidemiologically,
inﬂammation is usually estimated by measurement of circulating sub-
stances that are released as a cause or consequence of an inﬂammatory
response, and the most widely used biomarker for inﬂammation is C-
reactive protein (CRP). However, inﬂammation is a complex process,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of study population
Age (y) mean ± SD 70.0 ± 18.3
Sex, female (%) 213 (52.3)
METTS-Aa (%) 46 (11.3)/137 (32.7)/186 (45.7)/38 (9.3)
Oxygen saturation (%) mean ± SD 93.8 ± 6.1
Respiratory rate mean ± SD 23.7 ± 6.8
CRP (mg/dL) median (IQR) 8.4 (3.4-34.0)
CHF n (%) 145 (35.6)
COPD n (%) 112 (27.5)
Smokingb n (%) 107 (25.3)/214 (52.6)/77 (18.9)
a Four categories of METTS-A priority: 4/2/3/1, least critical to most critical.
b Three categories: nonsmokers/former smokers/active smokers.
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only partially be explained by CRP.
Although the main cause of dyspnea is usually established within a
few days of hospitalization, the physician in the ED is commonly sub-
jected to a patient with little information except brief medical history
and a state of acute dyspnea. Even in cases when the patient has one
or several known diseases which can cause acute dyspnea, for example,
CHF, COPD, and previous pneumonia, themain underlying cause and se-
verity of the current episode could be difﬁcult to assess. Therefore, we
chose to study an unselected patient population with acute dyspnea.
The aim of our study was to investigate if inﬂammatory biomarkers
predict 90-day mortality in this patient group.
The choice of inﬂammatory biomarkerswas based on the hypothesis
that inﬂammation may have a central role in many of the more malig-
nant underlying causes to acute dyspnea and that inﬂammatory bio-
markers therefore may be particularly useful to predict long-term
prognosis in this patient category.
2. Method
2.1. Study population
The study was conducted at the ED at the Skåne University Hospital
inMalmö (SUSMalmö), which serves a catchment area of approximate-
ly 400,000 inhabitants and has almost 85,000 annual visits. Adult pa-
tients that presented to the ED with the main symptom of acute
dyspnea between the 6th of March 2013 and the 29th of May 2014
were offered to participate in the study. Patients were only included
during ofﬁce hours, 6:45 AM to 4:30 PM, when a research nursewas pres-
ent. All patients were triaged to Medical Emergency Triage and Treat-
ment System–Adult score (METTS-A) category 1-4 (see explanation of
METTS-A below) and had routine blood chemistry performed.
Four-hundred thirty-nine patients were enrolled in the study. Of
these, 32 were excluded because of missing values of one of more of
the covariates used in the statistical analyses (see below), yielding a
total number of 407 patients that were included in the current study.
Medical Emergency Triage and Treatment System–Adult was mea-
sured according to standard procedures which was the standard tool
for triaging patients during the time of inclusion [5]. Medical Emergency
Triage and Treatment System–Adult is a 5-level triage tool combining
vital signs (oxygen saturation, respiratory rate, heart rate, blood pres-
sure, degree of consciousness, and body temperature) and symptoms.
The 5 levels are as follows: red (priority 1), life threatening; orange (pri-
ority 2), potentially life threatening; yellow (priority 3), not life threaten-
ing but in need of medical attention within 2 hours; green (priority 4),
not life threatening and not in need of immediate care; and blue (priority
0), not in need of emergency care and should be referred to primary care.
2.2. Clinical parameters
Respiratory rate was manually counted. Blood pressure, oxygen sat-
uration, and heart rate were measured with a fully automated
oscillometric device (CARESCAPE Monitor B850 or B650, General Elec-
tric Healthcare) [6,7], and degree of consciousness was determined ac-
cording to the Reaction Level Scale+[8]. After inclusion, patients were
asked about smoking habits in 3 categories (never smoked, former
smoker, and active smoker which included occasional smoker), preva-
lence of chronic diseases known to cause dyspnea (eg, CHF, COPD, asth-
ma, coronary artery disease, atrial ﬁbrillation, restrictive lung disease,
cancer, thromboembolic disease, rheumatic disease), and current med-
ication. Patient journals were examined by the research nurses to con-
ﬁrm previous diagnoses. Plasma concentration of CRP was measured
using a Radiometer ABL800 Flex machine [9] or Aﬁnion AS100 Analyzer
System [10]. Blood samples were collected immediately at presentation
with separation of serum and plasma and were frozen and stored at
−80°C for later analysis of biomarkers.2.3. Biomarker selection and measurement
The frozen blood samples were analyzed by the Proseek Multiplex
CVD I biomarker panel (Olink Bioscience, Uppsala, Sweden) which in-
cludes the 29 selected inﬂammatory markers chosen for revision in
the current study (Table 2). The method is a multiplex immunoassay
based on a Proximity Extension Assay [11]. For details, please see the
supplementary appendix.
Of the 29 selected inﬂammatory biomarkers, 4 were excluded be-
cause of chemically undetectable levels of the speciﬁc biomarker on
N98% of the collected samples.
All assay characteristics including detection limits and measure-
ments of assay performance and validations are available from theman-
ufacturer’s Web page [12].
The end pointwas all-causemortalitywithin 90 days frompresenta-
tion to the ED. The personal identiﬁcation number was linked to the na-
tional civil registry, in which survival status up to 90 days after
presentation was retrieved. If the patient had died, the date of death
was recorded.2.4. Statistical analysis
Because of skewed distributions of the biomarkers, the natural loga-
rithms were derived for the biomarker’s values and the values of CRP to
achieve statistical normality, and the log-transformed values were
expressed on a standardized scale (per 1-SD increment). Cox propor-
tional hazard models were created to relate each biomarker to the 90-
day mortality using time of presentation as the start of the follow-up
time and time of death as the end of follow-up if death occurred or to
the end of the study (90 days after presentation) if death did not
occur. Model 1 was adjusted for sex and age. The biomarkers with a P
valueb .05were then individually entered inmodel 2whichwas adjust-
ed for sex, age, METTS-A, oxygen saturation, respiratory rate, and CRP.
Biomarkers that had P value b .05 in model 2 were entered simulta-
neously in the Cox proportional hazard model and adjusted for the
same factors as in model 2. Biomarkers which were signiﬁcant in this
analysis and were also retained at a P value of b .05 in both forward
and backward selection were summed up to a score and weighted
using their β-coefﬁcients from the Cox proportional hazard model (ie,
β-coefﬁcient for biomarker 1 × z score of biomarker 1 + β-coefﬁcient
of biomarker 2 × z score of biomarker 2, etc). The sumof theseweighted
values of biomarkers was in turn expressed as multiples of 1 SD (z
score) and was ranked and ordered into quartiles. Additional adjust-
ments on top of model 2 were performed for comorbidities, smoking
(current, former, and never smoker) and the biomarker N-terminal of
the prohormone brain natriuretic peptide (NTproBNP). A P value of
b .05 was considered statistically signiﬁcant. The data were statistically
analyzed using IBM SPSS statistics 22 (SPSS Inc, Chicago, IL).
The study was approved by the regional ethics board of Lund,
Sweden, and followed the precepts established by the Declaration of
Helsinki.
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Clinical characteristics of the study population are shown in Table 1.
Themean age of the studypopulationwas70.0±18.3 years, 52.3%were
women, and themean respiratory ratewas 24±7min−1. Twohundred
forty-seven patients were admitted to a ward; of these, 88 were admit-
ted to a monitored ward (intensive care unit, coronary care unit, or
acute medical ward). During follow-up, 50 patients died; 44 of these
had been admitted to a ward at the time of presentation. In Table 2,
the result of model 1 (adjusted for sex and age) and model 2 (adjusted
for sex, age, METTS-A, oxygen saturation, respiratory rate, and CRP) is
presented. Twenty of the biomarkers showed a signiﬁcant association
with 90-day mortality and were subsequently entered in model 2. In
model 2, 16 of the biomarkers were signiﬁcantly associated with risk
of 90-day mortality. Using model 2 adjustments, the 16 biomarkers
were simultaneously entered into the Cox proportional hazard models
by forcing all 16 markers into the model as well as using both forward
and backward stepwise selection. Two biomarkers, interleukin-8 (IL-
8) and growth differentiation factor–15 (GDF-15), showed signiﬁcant
and independent association with 90-day mortality in all 3 analyses.
Each 1-SD increment of IL-8 was associated with increased risk of 90-
day mortality with a hazard ratio (HR) (95% conﬁdence interval [CI])
of 2.20 (1.67-2.90) (P = 2.5 × 10−8), and GDF-15 conferred an HR
(95% CI) of 3.45 (2.18-5.45) (P= 1.3 × 10−7). Apart from these 2 bio-
markers, age per year (1.04 [1.01-1.07], P = 0.007) and respiratory
rate (per min−1) (1.08 [1.03-1.13], P = 0.002) signiﬁcantly predicted
90-day mortality. C-reactive protein was not signiﬁcantly associated
with risk of 90-day mortality (HR [95% CI], 0.99 [0.72-1.35]; P= 0.94).
The summed biomarker mortality risk score of IL-8 and GDF-15
(BMRS) was strongly associated with risk of 90-day mortality, with
each 1-SD increment of the BMRS conferring an almost 4-fold increase
of the relative risk for death (Table 3). As shown in Table 3 and the
Figure, quartile analyses revealed that mortality was very low in sub-
jects with values less than the median of the summed biomarker score
and increased steeply over quartiles 3-4. In quartile 1, the 90-day mor-
tality was only 1%, whereas it increased to 32% in quartile 4.Table 2
Relationships between inﬂammatory biomarkers and risk of 90-day mortality
Biomarker HR (95% CI); age and sex adjusted P value HR (95% CI); age,
CCL4 1.41 (1.14-1.76) 1.9 × 10−3 1.34 (1.08-1.66)
CCL20 1.80 (1.36-2.40) 4.2 × 10−5 1.52 (1.10-2.11)
CD40-L 1.22 (0.91-1.64) NS
CHI3L1 1.70 (1.16-2.51) 7.0 × 10−3 1.45 (0.95-2.22)
CXCL1 1.57 (1.20-2.07) 1.2 × 10−3 1.47 (1.10-1.94)
ECP 1.28 (0.93-1.77) NS
SELE 1.25 (0.94-1.70) NS
CX3CL1 1.38 (1.01-1.87) 4.2 × 10−2 1.38 (1.03-1.84)
FS 1.98 (1.41-2.78) 7.5 × 10−5 1.83 (1.28-2.61)
GAL3 1.63 (1.25-2.13) 3.4 × 10−4 1.59 (1.21-2.08)
GDF15 3.51 (2.29-5.38) 7.9 × 10−9 3.45 (2.18-5.45)
hK11 1.47 (1.10-1.95) 8.5 × 10−3 1.54 (1.16-2.03)
IL-1-RA 1.49 (1.11-2.00) 8.1 × 10−3 1.19(0.83-1.72)
IL-6 1.99 (1.44-2.76) 3.7 × 10−5 1.72(1.16-2.57)
IL-6-RA 1.47 (1.07-2.02) 1.8 × 10−2 1.50 (1.08-2.08)
IL-8 2.29 (1.80-2.91) 1.1 × 10−11 2.20 (1.67-2.90)
IL-16 1.28 (0.95-1.73) NS
IL-18 1.42 (1.10-1.82) 6.6 × 10−3 1.27 (0.97-1.65)
IL-27-A 1.97 (1.38-2.81) 2.0 × 10−4 1.69 (1.13-2.53)
LOX-1 1.90 (1.36-2.65) 1.8 × 10−4 1.68 (1.18-2.40)
MCP1 1.60 (1.21-2.12) 1.0 × 10−3 1.52(1.16-2.01)
NEMO 1.34 (1.01-1.78) 4.6 × 10−2 1.21 (0.90-1.63)
RAGE 1.16 (0.85-1.59) NS
ST2 3.42 (2.22-5.27) 2.6 × 10−8 3.22 (1.96-5.29)
U-PAR 2.46 (1.64-3.69) 1.3 × 10−5 2.12 (1.37-3.25)
C-Cmotif chemokine 4 (CCL4), C-Cmotif chemokine 20 (CCL20), CD40-ligand (CD40-L), chitina
(ECP), E-selectin (SELE), fractalkine (CX3CL1), follistatin (FS), galectin-3 (GAL3), growth differe
protein (IL-1-RA), interleukin 6 (IL-6), interleukin 6 receptor subunit alpha (IL-6-RA), interleuk
27-A), lectin-like oxidized LDL receptor 1 (LOX-1), monocyte chemotactic protein 1 (MCP1), NF
(RAGE), ST2 protein (ST2), urokinase plasminogen activator surface receptor (U-PAR).Smoking, history of CHF, history of COPD, and the biomarker NT-
proBNP were added to model 2 adjustments, but this did not affect
the relationship between the BMRS and 90-day mortality. N-terminal
of the prohormone brain natriuretic peptide was not signiﬁcantly asso-
ciated with 90-day mortality in this study population.
4. Discussion
The key ﬁndings of the current studywas that IL-8 andGDF-15,mea-
sured in plasma collected immediately upon entry to the ED, individual-
ly and in aggregate strongly and independently predict risk of 90-day
mortality in patients with acute dyspnea. In patients with values less
than the median values of the BMRS (ie, sum of standardized values of
IL-8 andGDF-15),mortality was only 2%, whereas it was 32% in patients
in the top quartile, with a multivariate adjusted relative risk of 13 in top
vs bottom quartile of the BMRS. This demonstrates for the ﬁrst time that
inﬂammatory biomarkers can predict mortality in patients presenting
with acute dyspnea irrespective of underlying pathology. Whereas
there are previous studies examining the prognostic value of few select-
ed biomarkers in CHF [13] and lower respiratory tract infections [14],
we are not aware of any prior study on a broad set of inﬂammatory bio-
markers, taken upon presentation to the ED, in unselected patients with
acute dyspnea. It is also important to recognize that the BMRS and 90-
day mortality were not affected by adjustment for prevalence of COPD
and CHF in this study, making the BMRS more important than current
pathology in assessing prognosis.
Since the P values for the BMRS where shown to be solid and with-
stand using of the Bonferroni correction, we do not thinkmultiple com-
parisons when testing 25 different inﬂammatory biomarkers have
ﬂawed our key results. The weakest P value (P for trend over quartiles
of the BMRS) gives us a corrected PBonnferroni = 2 × 10−6 × 25 = 5 ×
10−5, demonstrating that the signiﬁcance of the results is solid.
Along with an aging population, which inevitably leads to increased
occurrence of both acute and chronic diseases, there is an escalating de-
mand on the health care system to use its resources more efﬁciently
without compromising medical safety and quality of care. As the mainsex, METTS-A, oxygen saturation, respiratory rate, and CRP adjusted P value
8.0 × 10−3
1.2 × 10−2
NS
8.1 × 10−3
3.2 × 10−2
8.9 × 10−4
7.5 × 10−4
1.3 × 10−7
2.7 × 10−3
NS
7.1 × 10−3
1.5 × 10−2
2.5 × 10−8
NS
1.0 × 10−2
4.4 × 10−3
2.8 × 10−3
NS
4.2 × 10−6
7.1 × 10−4
se-3-like protein 1 (CHI3L1), C-X-Cmotif chemokine 1 (CXCL1), eosinophil cationic protein
ntiation factor 15 (GDF15), human kallikrein 11 (hK11), interleukin 1 receptor antagonist
in 8 (IL-8), interleukin 16 (IL-16), interleukin 18 (IL-18), interleukin 27 subunit alpha (IL-
-kappa-B essential modulator (NEMO), receptor for advanced glycosylation end products
Table 3
Multivariate adjusted HRs for the biomarker mortality score in relation to 90-day mortality
All patients P value Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend
N/n events 407/50 101/1 102/2 102/14 102/32
HR (95% CI)a 3.79 (2.50-5.73) 3.2 × 10−10 1 (Ref) 0.91 (0.08-10.56) 5.25 (0.63-43.62) 13.17 (1.60-108.46) 2.0 × 10−6
a Adjusted for age, sex, METTS-A, oxygen saturation, respiratory rate, and CRP.
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cation tools which may help the ﬁrst-line physician at the ED to decide
on level of care, as well as the correct level of follow-up, are becoming
increasingly important. In this context, biomarkers are attractive candi-
dates given their relatively low cost, their potential for generating re-
sults fast, and that patients are not exposed to radiation or other risks.
Our ﬁndings have several potential clinical implications. Themortal-
ity within 90 days in the patient population was high (12%). Given the
relatively short follow-up time, deaths occurring within that time
frame have a high likelihood of having a relationship with the acute ill-
ness underlying the acute dyspnea for which the patients sought help.
Thus, risk of long-term mortality is likely to be a good proxy of the se-
verity of the acute underlying illness. Given the large difference in 90-
day mortality between patients in quartiles 1-2 and quartile 4 of the
BMRS (Figure), measurement of IL-8 and GDF-15, upon presentation
to the ED, in patients with acute dyspnea may be a valuable comple-
mentary support for the ﬁrst-line physician to make decisions to safely
send home patients with low values of the BMRS and provide follow-up
in primary care or no follow-up at all. Furthermore, as one-third of pa-
tients in the top quartile of the BMRS died within 90 days, such high
values may support prioritization of more intensive care. In addition,
given the high 90-day mortality in patients with high BMRS values,
such patients may require extra attention after being discharged from
the hospital or, in the presence of no clinical indication for immediate
admission, a close follow-up at a hospital outpatient clinic. Importantly,
the BMRS performed much better than and was statistically indepen-
dent of initial vital signs, CRP, comorbidities, and the triage algorithm
score used (METTS-A), the latter of which has previously been shown
to predict in-hospital mortality [5].
We focused the study on unselected patients with acute dyspnea
rather than at selected groups of patients with a speciﬁc main diagnosis
(eg, CHF, COPD, or infection). The reason for doing this was that we
wanted to identify biomarkers which are helpful upon immediate pre-
sentation at the ED. This is when the ﬁrst-line physician who meetsFigure. Kaplan-Meier plot showing cumulative mortality during 90 days of follow-up.
Quartile 1 denotes the lowest values of the BMRS; and Quartile 4, the highest values.the patient commonly has limited or no access at all to what may be
the underlying main diagnosis.
All of the conditions underlying acute dyspnea have different treat-
ment plans, making it important to ﬁnd the underlying cause. The
BMRSmaymotivate further examination and extensivemedical testing.
For example, in a patientwith a high BMRS, itmay bemore important to
use more advanced examinations early to ﬁnd the exact underlying
cause, possibly staging and beginning short-term and long-term treat-
ment quickly. In a patient with a low BMRS, such urgency is lower,
and further examinations could be decided upon later on and when
needed in primary care. This would aid in prioritizing and distributing
the time assets and monetary assets of the ED, and also in health care
in general, and studies speciﬁcally addressing these aspects are war-
ranted in the future.
Interleukin-8, also known as chemokine (C-X-Cmotif) ligand 8, is pro-
duced by macrophages, monocytes, ﬁbroblasts, epithelial cells, and en-
dothelial cells. It induces chemotaxis for naive T cells and mobilizes
and activates neutrophils and angiogenesis [15]. It is produced quickly
as a reaction and progressor of inﬂammation. It is already in some clin-
ical use as an earlymarker of neonatal sepsis and systemic inﬂammation
[16].
Growth differentiation factor–15 is part of the transforming growth
factor β family (TGF-β superfamily). It is known under many names, for
example, macrophage inhibitory cytokine, NSAID-activated gene,
prostate-derived factor, placental bone morphogenetic protein, placen-
tal TGF-β, and PL74. It is a regulatory protein in the inﬂammatory path-
way. Growth differentiation factor–15 is found in all tissues but is only
physiologically active in the placenta where it is thought to ensure the
survival of the fetus by inhibiting the mother’s immune response. It is
however present and active in many pathologies, for example, cancer,
cardiopulmonary disease, renal failure, diabetes, and congenital anemia.
A high level of GDF-15 has been associatedwith an increased risk of car-
diovascular events and with more malignant phenotypes of many tu-
mors [17]. Growth differentiation factor–15 has been shown to be
associated with a higher mortality irrespective of the cause of death
[18]. It is not yet in clinical use.
According to the latter facts on the biomarkers in addition to our
data, inﬂammation is a contributor or indicator of the mortality in the
study population. The inﬂammation in our study population could how-
ever not be shown by using the traditional CRP. C-reactive protein is in-
creased in systemic inﬂammation, viral infections, and bacterial
infections and is particularly high in sepsis [15]. Our results do not pre-
clude CRP from being important in aiding in the diagnostic process;
however, its prognostic value in terms of 90-daymortality in acute dys-
pnea patients seems limited.
4.1. Limitations
Both COPD andCHF are characterized by increased inﬂammatory ac-
tivity, and they are both associated with markedly reduced life expec-
tancy and commonly present themselves with dyspnea. As stated
previously, we were therefore surprised that we could show no rela-
tionship between 90-day mortality and the presence of CHF or COPD.
However, we acknowledge that the information available inmedical re-
cords combined with the patient’s own reported medical history may
not be fully accurate and does not take into account factors of impor-
tance for survival such as duration and severity of these diseases
[19,20]. This is, however, a limitation which is also commonly present
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pose the biomarkers to be used.
In the current study, we cannot draw any conclusions as to whether
IL-8 and GDF-15 are bystanders, correlating with the underlying patho-
physiology or whether they may be causally involved in the acute dis-
ease process.
Although the nominal differences of numbers of deaths and point es-
timates of HRs in top vs bottom quartileswere large, onemust remember
that the CIswerewide, and thus thepoint estimates should be interpreted
with caution. This is a consequence of relatively low numbers of patients
and events in each quartile. On the other hand, in the analyses of the con-
tinuous relationship between the BMRS (as well as IL-8 and GDF-15 indi-
vidually) and the risk of 90-day mortality, where the average risk per 1-
SD increase was calculated, the statistical signiﬁcance was strong and
CIs narrower. Hence, we suggest that the BMRS does provide strong inde-
pendent information on 90-daymortality risk. However, larger multicen-
ter studies are warranted to deﬁne the most clinically important cutoff
values (top and bottom quartiles or quintiles etc)
Ninety days is a commonly used follow-up time in ED-based bio-
marker studies; it may intuitively be regarded as a long time to evaluate
mortality in acute conditions. In-hospital mortality is one alternative
end point, which however does not standardize the follow-up time,
and 30-day mortality is another alternative end point, both of which
are likely to have a relation to the acute illness underlying the dyspnea.
On the other hand, if we had chosen a shorter follow-up time, that
would have been at the expense of missing some deaths which indeed
were related to the acute illness presenting as dyspnea at the ED. The
Kaplan-Meier plot (Figure) shows an almost constant proportionality
over 90 days, suggesting that the HR would have been equally high
using a 30-day end point.
A relatively long follow-up time would be particularly important
when considering the potential clinical implication of using the BMRS
to identify patients with low values and low risk and using this as sup-
port to safely discharge themwith little or noneed for follow-up. Ninety
days of follow-up therefore appears to be a decent compromise both to
guide decisions prioritizing higher level of care or need of close short-
term follow-up and to support safe discharge.
5. Conclusion
Our results show that a biomarker risk score of IL-8 and GDF-15 is a
strong predictor of 90-daymortality in patients in an emergency setting
with acute dyspnea, independently of vital signs, triage priority, CRP,
and important comorbidities. Therefore, Biomarker Risk Score (BMRS)is suggested to be used at the ED to identify patients with a higher
need of medical attention and management. It may also turn out to be
useful to support the EDphysician’s decision to safely discharge patients
with a low risk of mortality.
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